Brief: ExpreS2ion's Joint Venture AdaptVac Signs Final License Agreement With Bavarian Nordic On COVID-19 Vaccine

ExpreS2ion Biotech Holding AB

22/07/2020 07:06

July 22 (Reuters) - ExpreS2ion Biotech Holding AB
 EXPRS2.ST :
    * EXPRES2ION'S JOINT VENTURE ADAPTVAC SIGNS FINAL LICENSE
AGREEMENT WITH BAVARIAN NORDIC ON COVID-19 VACCINE
    * JOINT VENTURE ADAPTVAC HAS ENTERED INTO A FINAL LICENSE
AGREEMENT WITH BAVARIAN NORDIC A/S
    * AGREEMENT WITH BAVARIAN NORDIC A/S TO LICENSE PROPRIETARY
CAPSID
VIRUS LIKE PARTICLE (CVLP) BASED SARS-COV-2 SUBUNIT VACCINE
    * EXPRES(2)ION WILL RETAIN UP TO EUR 2 MILLION,
CORRESPONDING TO
SEK 21 MILLION, OF COMMERCIAL MILESTONE PAYMENTS, WHICH ARE
ESTIMATED TO BE RECOGNISED AS EXPRES(2)ION REVENUES DURING 2021
AND 2022
    * TOTAL DEAL VALUE, EXCLUDING ROYALTIES IS UP TO EUR 136
MILLION,
CORRESPONDING TO SEK 1.4 BILLION

Source text for Eikon:  ID:nWkrbD3xzQ 
Further company coverage:  EXPRS2.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))